維生素 B 群（綜合 B 群 / B-Complex） B-Complex Vitamins (B1, B2, B3/Niacin, B5, B6, B7/Biotin, B9/Folate, B12) × 同半胱胺酸（高同半胱胺酸血症與心血管預防）
結論：主流反證據
raw score=U 但 L11 獨評 D / 建議 counter_evidence + 有 ≥1 efficacy-against (L5 against=4, L4 against=0, HEC=HEC-NONE) — 升 counter_evidence (B4-2 U-tier escalation)
U ⚫ U 未驗證 主流反證據 🚨 high — heavy affiliate marketing in TW community
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.23
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
U · 主流反證據
信心度
90%
證據方向一致性高
證據層級
E1
Cochrane 高品質系統性回顧／統合分析
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.227
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
Homocysteine lowering with folic acid and B vitamins in vascular disease (HOPE-2 trial, Lonn et al., NEJM)
結論：Mean plasma homocysteine decreased 2.4 µmol/L in the active arm and rose 0.8 µmol/L in placebo. Despite this clear surrogate effect, the primary composite endpoint occurred in 18.8% of active vs 19.8% of placebo (RR 0.95, 95% CI 0.84-1.07, p=0.41). MI was unchanged; cardiovascular death was unchanged; stroke was modestly reduced (RR 0.75, 95% CI 0.59-0.97). Hospitalization for unstable angina was significantly increased (RR 1.24, 95% CI 1.04-1.49). Net conclusion: homocysteine lowering does not reduce major cardiovascular events in patients with vascular disease.
前往 PubMed
Homocysteine lowering and cardiovascular events after acute myocardial infarction (NORVIT trial, Bonaa et al., NEJM)
結論：Folic acid + B12 reduced plasma homocysteine by 27%. Despite this, primary composite occurred in 18.0% of folic acid + B12 + B6, 16.5% of folic acid + B12, 17.1% of B6 alone, and 16.2% of placebo. Combined folic acid + B12 + B6 produced a non-significant trend toward HARM (RR 1.22, 95% CI 1.00-1.50, p=0.05). No benefit observed in any active arm; signal of increased risk with the triple combination.
前往 PubMed
Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death (VISP trial, Toole et al., JAMA)
結論：Mean homocysteine reduction 2 µmol/L greater in high-dose vs low-dose arm. Recurrent ischemic stroke risk was equivalent between arms (HR 1.0, 95% CI 0.8-1.3) at 2 years; combined endpoint of stroke, CHD event, or death also showed no difference (HR 1.0, 95% CI 0.8-1.1). Conclusion: moderate homocysteine reduction had no effect on vascular event rates after stroke. Note: background U.S. folate fortification began during the trial (1998), which may have blunted differential effects.
前往 PubMed
Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors (SEARCH trial, Armitage et al., JAMA)
結論：Allocation to folic acid + B12 reduced homocysteine by 3.8 µmol/L (28%). Primary major vascular event occurred in 25.5% of B-vitamin arm vs 24.8% of placebo (risk ratio 1.04, 95% CI 0.97-1.12, p=0.28). No effect on major coronary events, stroke, revascularisation, vascular mortality, or all-cause mortality. Largest single homocysteine-lowering trial; findings definitive for null effect on hard CV outcomes in secondary prevention.
前往 PubMed
Effect of combined folic acid, vitamin B6, and vitamin B12 on cardiovascular events in women: WAFACS (Albert et al., JAMA)
結論：Plasma homocysteine reduced 18.5% in active vs placebo. Primary composite occurred in 14.9% of active vs 14.3% of placebo (RR 1.03, 95% CI 0.90-1.19, p=0.65). No effect on individual outcomes including MI (RR 1.04), stroke (RR 1.14), revascularisation (RR 1.00), or CV death (RR 0.92). Despite robust homocysteine reduction over >7 years in high-risk women, no clinical benefit observed.
前往 PubMed
Homocysteine-lowering interventions for preventing cardiovascular events (Cochrane systematic review, Marti-Carvajal et al.)
結論：Pooled across 15 RCTs (n=71,422): no effect of homocysteine-lowering interventions on non-fatal/fatal MI (RR 1.02, 95% CI 0.95-1.10; high-quality evidence), all-cause mortality (RR 1.01, 95% CI 0.96-1.06), or cardiovascular mortality. Borderline reduction in stroke (RR 0.90, 95% CI 0.82-0.99) appearing only in trials conducted in regions WITHOUT folate fortification and dominated by Chinese trial CSPPT. Authors conclude no convincing evidence supporting homocysteine-lowering for CV event prevention.
前往 PubMed
L4a US FDA
支持
As part of a well-balanced diet, rich in fresh fruits and vegetables, daily intake of at least 400 mcg folic acid, 3 mg vitamin B6 and 5 mcg vitamin B12 may reduce the risk of vascular disease. 來源↗
L4b EU EFSA
支持
a cause and effect relationship has been established between the dietary intake of niacin and contribution to normal energy-yielding metabolism 來源↗
L4c UK NHS
謹慎
Taking 200mg or more a day of vitamin B6 can lead to a loss of feeling in the arms and legs known as peripheral neuropathy. ... Do not take more than 10mg of vitamin B6 a day in supplements unless advised to by a doctor. 來源↗
L4d TW TFDA / 衛福部
支持
目前公告之保健功效項目為：胃腸功能改善、調節血脂、護肝、骨質保健、免疫調節、輔助調整過敏體質、不易形成體脂肪、調節血糖、輔助調節血壓、抗疲勞、延緩衰老、輔助調節血鐵、牙齒保健、膝關節保健 來源↗
L4e WHO
謹慎
Vitamins B and E, PUFA and multi-complex supplementation should not be recommended to reduce the risk of cognitive decline and/or dementia. 來源↗
L5a NIH Office of Dietary Supplements
謹慎
B vitamins lower blood homocysteine concentrations, but several large clinical trials found that this reduction did not lower the risk of cardiovascular events. 來源↗
L5b Mayo Clinic
反對
Vitamin B-12 and other B vitamins may help lower homocysteine levels. However, researchers haven't found that lowering homocysteine levels lowers the risk of heart and blood vessel disease. 來源↗
L5c Cleveland Clinic
反對
your healthcare provider may recommend taking supplements of: Vitamin B6, Vitamin B12, Folic acid ... But increasing your vitamin intake alone doesn't reduce your risk of heart disease. 來源↗
L5d Harvard Health
反對
Several large randomized trials of B vitamin supplements to lower homocysteine levels and prevent heart disease and stroke failed to find a benefit. 來源↗
L5e Specialty Society (condition-mapped)
反對
Current guidelines, such as the American Heart Association (AHA), do not recommend neither B-vitamin supplementation nor routine screening for elevated homocysteine levels. 來源↗
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽
台灣社群幾乎沒有「B 群降同半胱胺酸」的實測討論——此題在地論述被醫療／業配商業媒體（康健、ETtoday、聯安/榮新診所、微笑藥師）壟斷。PTT/Dcard/Mobile01 的 B 群討論集中於提神、抗疲勞、痘痘、孕期，僅見零星健檢紅字貼文（如 Mobile01 體檢同半胱胺酸偏高），但無補 B 群後指數下降的鄉民心得。
💬社群實感
無共識（社群幾乎無針對『B 群降同半胱胺酸』的實測心得；零星健檢紅字貼文未追蹤補充後成效）
破解迷思 社群最常見的 2 個誤解
✕
迷思把 B 群當提神／抗疲勞用，與『代謝同半胱胺酸、保護心血管』這個機制完全脫鉤
✓
事實社群罕有人把兩者連結
✓
事實誤以為一般綜合 B 群劑量即足以降同半胱胺酸（醫療端強調關鍵是葉酸 B9、B6、B12 三者，且需依檢驗值補充並複檢，而非隨意吃市售 B 群）
- 葉酸（folic acid）治療
- 維生素 B12 合併治療
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-homocysteine-INT-b-vitamins-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "維生素 B 群（綜合 B 群 / B-Complex）能改善同半胱胺酸（高同半胱胺酸血症與心血管預防）",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"alternateName": "證據不足 (Insufficient evidence)"
}
}